medigraphic.com
ISSN 0016-3813 (Print)

2015, Number 5

<< Back Next >>

Gac Med Mex 2015; 151 (5)

Resistance to antibiotic: A serious global problem

Ponce de León-Rosales S, Arredondo-Hernández R, López-Vidal Y

Language: Spanish
References: 53
Page: 681-689
PDF size: 93.01 Kb.


ABSTRACT

An important piece of improvement in public health standards, medicine achievements, and development is based on the impressive effect of vaccines and antibiotics on infectious diseases. However, the last three or so decades have witnessed how an unsound use of antibiotics has resulted in antibiotic multi-resistant clones in hospitals and community environments. It also has been said that antibiotic research and the development pipeline has crashed, leading to no new antibiotic molecules to be tested at a time of treatment failure, manifest with unacceptable frequency as an increased economic and human cost in lives.
Like the name of the series, antibiotic resistance is a global problem with clear evolutionary roots and a broad local impact. In that sense, this review explores the interaction among resistant mechanisms, underlying motives of expansion and actual trends in antibiotic resistance upgrade to limit the problem. Conceivably, only the involvement of players at every level, and coordinated actions accordingly constitute the necessary elements for effectively intervention.


REFERENCES

  1. Martínez JL. Antibiotics and antibiotic resistance genes in natural environments. Science. 2008;321(5887):365-7.

  2. Wellington EMH, Boxall AB, Cross P, et al. The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteria. Lancet Infect Dis. 2013;13(2):155-65.

  3. Schmalstieg F, Goldman A. Birth of the science of immunology. J Med Biogr. 2010;18(2):88-98.

  4. Galán JC, González-Candelas F, Rolain JM, et al. Antibiotics as selectors and accelerators of diversity in the mechanisms of resistance: from the resistome to genetic plasticity in the 􀁠-lactamases world. Front Microbiol. 2013;4:9.

  5. Jacoby GA, Munoz-Price LS. The Newb-Lactamases. N Engl J Med. 2005;352:380-91.

  6. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial- resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29(11):996-1011.

  7. Hidron AI, Low CE, Honig EG, et al. Grand Round Emergence of community- acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Case presentation. 2009;9(junio).

  8. Otter JA, French GL. Community-associated meticillin-resistant Staphylococcus aureus strains as a cause of healthcare-associated infection. J Hosp Infect. 2011;79(3):189-93.

  9. Liu Y-M, Chen Y-S, Toh H-S, et al. In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents. 2012;40 Suppl:S11-7.

  10. WHO MS. Draft Global Action Plan on Antimicrobial Resistance. 2014:1-20.

  11. Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res. 2005;36(6):697-705.

  12. Arias CA, Murray BE. Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge. N Engl J Med. 2009;360(5):439-43.

  13. Walsh C. Antibiotics: Actions, Origins, Resistance. Washington,D.C: ASM Press; 2003.p. 335.

  14. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46 (Suppl 5):S344-9.

  15. Guzmán-Blanco M, Labarca JA, Virginia M. Review article. Extended spectrum 􀁠-lactamase producers among nosocomial Enterobacteriaceae in Latin America. Braz J Infect Dis. 2014;18(4):421-33.

  16. Hughes D, Andersson DI. Selection of resistance at lethal and non-lethal antibiotic concentrations. Curr Opin Microbiol. 2012;15(5):555-60.

  17. Michael I, Rizzo L, McArdell CS, et al. Urban wastewater treatment plants as hotspots for the release of antibiotics in the environment: a review. Water Res. 2013;47(3):957-95.

  18. Rizzo L, Manaia C, Merlin C, et al. Urban wastewater treatment plants as hotspots for antibiotic resistant bacteria and genes spread into the environment: a review. Sci Total Environ. 2013;447:345-60.

  19. Udikovic-Kolic N, Wichmann F, Broderick NA, et al. Bloom of resident antibiotic-resistant bacteria in soil following manure fertilization. Proc Natl Acad Sci USA. 2014;111(42):15202-7.

  20. Baquero F. Metagenomic epidemiology: a public health need for the control of antimicrobial resistance. Clin Microbiol Infect. 2012;18 (Suppl 4):67-73.

  21. Armstrong GL, Conn LA, Pinner RW. Trends in Infectious Disease Mortality in the United States During the 20th Century. JAMA. 1999;281(1):61-6.

  22. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1-12.

  23. Nathwani D. Health economic issues in the treatment of drug-resistant serious Gram-positive infections. J Infect. 2009;59 (Suppl 1):S40-50.

  24. Little P, Merriman R, Turner S, et al. Presentation, pattern, and natural course of severe symptoms, and role of antibiotics and antibiotic resistance among patients presenting with suspected uncomplicated urinary tract infection in primary care: observational study. BMJ. 2010;340:b5633.

  25. Zaidi MB, Estrada-García T, Campos FD, et al. Incidence, clinical presentation, and antimicrobial resistance trends in Salmonella and Shigella infections from children in Yucatan, Mexico. Front Microbiol. 2013;4:288.

  26. Lander E, Chyba C, Holdren J, et al. REPORT TO THE PRESIDENT ON.; 2014.

  27. Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14(8):742-50.

  28. Reardon S. Antibiotic resistance sweeping developing world. Nature. 2014;509(7499):141-2.

  29. Okeke IN, Laxminarayan R, Bhutta ZA, et al. Antimicrobial resistance in developing countries. Part I : recent trends and current status. Lancet Infect Dis. 2005;5:481-93.

  30. Jones RN, Guzman-Blanco M, Gales AC, et al. Original article susceptibility rates in Latin American nations : report from a regional resistance surveillance program ( 2011 ). 2013;7(6):672-81.

  31. PAHO U. Informe Anual de La Red de Monitoreo / Vigilancia de La Resistencia a Los Antibióticos; 2005.

  32. Hamdan-Partida A, Sainz-Espuñes T, Bustos-Martínez J. Isolation of community-acquired methicillin-resistant Staphylococcus aureus in healthy carriers in a Mexican community. Int J Infect Dis. 2014;18: 22-6.

  33. Gales AC, Castanheira M, Jones RN, et al. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis. 2012;73(4):354-60.

  34. Zaidi M, Sifuentes-Osornio J, Rolón AL, et al. Inadequate Therapy and Antibiotic Resistance. Risk Factors for Mortality in the Intensive Care Unit. Arch Med Res. 2002;33(3):290-4.

  35. González A, Ponce de León S, Ruiz G. Cefalosporinas de tercera generación: las dos caras de la moneda. Salud Publica Mex.1985;27: 479-84.

  36. Ruiz-Palacios G, Ponce de León S, Sifuentes J. Control de la resistencia de bacilos Gram negativos a aminoglucósidos. Rev Invest Clin. 1986;38:1-6.

  37. Garcia E, Sierra J, Ponce de León S. Uso de antibióticos en la consulta externa del Instituto Nacional de Nutrición. Rev Invest Clin. 1991;43: 113-8.

  38. Hammerum AM, Larsen J, Andersen VD, et al. Characterization of extended- spectrum 􀁠-lactamase (ESBL)-producing Escherichia coli obtained from Danish pigs, pig farmers and their families from farms with high or no consumption of third- or fourth-generation cephalosporins. J Antimicrob Chemother. 2014;69(10):2650-7.

  39. Mole BYB. Farming up trouble. Nature. 2013;499:2007-9.

  40. Agersø Y, Aarestrup FM. Voluntary ban on cephalosporin use in Danish pig production has effectively reduced extended-spectrum cephalosporinase- producing Escherichia coli in slaughter pigs. J Antimicrob Chemother. 2013;68(3):569-72.

  41. Norrby S, Nord C, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis. 2005; 5(2):115-9.

  42. Idsa Public. The 10 x ’20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010; 50(8):1081-3.

  43. Spellberg B, Rex JH. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nat Rev Drug Discov. 2014;11(2):1-7.

  44. Shlaes DM, Sahm D, Opiela C, et al. The FDA reboot of antibiotic development. Antimicrob Agents Chemother. 2013;57(10):4605-7.

  45. Brötz-Oesterhelt H, Sass P. Postgenomic strategies in antibacterial drug discovery. Future Microbiol. 2010;5(10):1553-79.

  46. Tavares LS, Silva CSF, de Souza VC, et al. Strategies and molecular tools to fight antimicrobial resistance: resistome, transcriptome, and antimicrobial peptides. Front Microbiol. 2013;4:412.

  47. Tomayko JF, Rex JH, Tenero DM, et al. The challenge of antimicrobial resistance: new regulatory tools to support product development. Clin Pharmacol Ther. 2014;96(2):166-8.

  48. Currie CJ, Berni E, Jenkins-Jones S, et al. Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis. BMJ. 2014;349:g5493..

  49. Dwyer DJ, Belenky PA, Yang JH, et al. Antibiotics induce redox-related physiological alterations as part of their lethality. Proc Natl Acad Sci USA. 2014;111(20):E2100-9.

  50. Martínez JL, Baquero F, Andersson DI. Predicting antibiotic resistance. Nat Rev Microbiol. 2007;5(12):958-65.

  51. Yi l. NIH Public Access. Anal Chem. 2013;85(8):3971-6.

  52. Bouchillon S, Hoban DJ, Badal R, et al. Fluoroquinolone Resistance Among Gram-Negative Urinary Tract Pathogens: Global Smart Program Results, 2009-2010. Open Microbiol J. 2012;6:74-8.

  53. Hollis A, Ahmed Z. Preserving antibiotica, rationally. N Engl J Med. 2013;369(26):2472-4.




2020     |     www.medigraphic.com